Zinzino AB Highlights Impressive Growth in Q1 2025
In an impressive testament to its operational strength, Zinzino AB has announced notable revenue growth for the first quarter of 2025. Rising to SEK 723.7 million from SEK 454.5 million indicates a significant growth rate of 59% compared to the same period last year. This remarkable surge reflects Zinzino's robust market position and its dedication to delivering high-quality health products to consumers.
Strong Financial Performance
During this quarter, Zinzino achieved a substantial growth in EBITDA, reaching SEK 78.8 million, which reflects an increase from SEK 51.7 million in the prior year. Although the EBITDA margin decreased slightly to 10.9% from 11.4%, the overall financial indicators demonstrate a positive trajectory. The strong cash flow from operating activities, amounting to SEK 21.1 million, also highlights the company’s solid operational health.
Strategic Acquisitions Boosting Market Presence
One pivotal aspect of Zinzino's recent success is its strategic acquisition of Zurvita's assets along with its distributor and customer database. This acquisition has significantly fortified Zinzino’s presence in North America and presented opportunities for growth in the region. Furthermore, the company has recently launched its products in New Zealand, further extending its global footprint.
Future Developments and Expansion Plans
Exciting developments continue for the company with the announcement of acquiring assets from the US-based Valentus Global. This move aims to enhance Zinzino's distribution capabilities within Europe, corroborating its commitment to expanding its market reach across different regions.
Financial Overview: January to March
A quick look at key financial details from the first quarter reveals:
- Total revenue: SEK 723.7 million (up from SEK 454.5 million)
- Gross profit: SEK 223.6 million (compared to SEK 160.9 million)
- Gross profit margin: 30.9% (down from 35.4%)
- EBITDA: SEK 78.8 million (increased from SEK 51.7 million)
- EBITDA margin: 10.9% (slightly lower than the previous quarter)
- Dividend proposal of SEK 4.00 per share, totaling SEK 143.1 million
Company Contact and Support
For further inquiries, Zinzino CEO Dag Bergheim Pettersen is available at +47 (0) 932 25 700. CFO Fredrik Nielsen can also be contacted at +46 (0) 707 900 174 for detailed financial guidance.
A Focus on Innovation and Quality
Founded on delivering personalized health solutions, Zinzino specializes in development and distribution of test-based supplements. The company is committed to leveraging scientific research in all its products, which are currently available in over 100 markets globally.
Overview of Zinzino’s Market Position
As a public limited company, Zinzino is listed on Nasdaq First North Premier Growth Market, and its diverse portfolio continues to grow through acquisitions, including notable brands in health and wellness. The integration of brands such as Cleanthi Alpha-Olenic LTD further bolsters its product offering, showcasing a commitment to quality and sustainability.
Frequently Asked Questions
What are the key highlights from Zinzino's Q1 2025 report?
Zinzino reported a revenue increase to SEK 723.7 million, marking a 59% growth, alongside a noteworthy EBITDA rise to SEK 78.8 million.
How has Zinzino's market presence changed recently?
The company expanded its reach with the acquisition of Zurvita's assets and the launch of its products in New Zealand.
What was the EBITDA margin for the quarter?
The EBITDA margin for the first quarter of 2025 was 10.9%, slightly down from 11.4% in the previous year.
Who can be contacted for more information on Zinzino's financial status?
Questions can be directed to CEO Dag Bergheim Pettersen at +47 (0) 932 25 700 or CFO Fredrik Nielsen at +46 (0) 707 900 174.
What is Zinzino's strategy for growth?
Zinzino aims to enhance its market position through strategic acquisitions, product innovation, and expanding its distribution channels across Europe and North America.
